MARKET

AIMT

AIMT

Aimmune
NASDAQ

Real-time Quotes | Nasdaq Last Sale

31.30
-0.29
-0.92%
After Hours: 31.30 0 0.00% 17:01 12/13 EST
OPEN
30.59
PREV CLOSE
31.59
HIGH
31.50
LOW
30.26
VOLUME
865.44K
TURNOVER
--
52 WEEK HIGH
32.22
52 WEEK LOW
16.95
MARKET CAP
1.98B
P/E (TTM)
-8.0958
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of AIMT and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

AIMT News

  • Aimmune: High Probability Events Approaching
  • Seeking Alpha - Article.2d ago
  • Credit Suisse cuts view on Gilead in premarket analyst action
  • Seeking Alpha - Article.2d ago
  • Credit Suisse Downgrades Aimmune Therapeutics to Neutral
  • Benzinga.2d ago
  • Cramer Gives His Opinion On Synopsys, Cisco And More
  • Benzinga.3d ago

More

Industry

Biotechnology & Medical Research
+1.07%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Name
Price
%Change

About AIMT

Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. The Company's lead CODIT product candidate, AR101, is an investigational biologic for the treatment of patients with peanut allergy. The Company has initiated Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE), its Phase III registration trial of AR101. The Company is in the process of evaluating additional delivery forms for AR101 for the maintenance phase.
More

Webull offers Aimmune Therapeutics Inc (AIMT) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.